Lipoprotein Associated Phospholipase A2 （Lp-PLA2）
Kit Name: Lipoprotein Associated Phospholipase A2 Detection Kit
Method: Fluorescence dry quantitative immunoassay
Assay measuring range: 5ng/mL~800ng/mL
Incubation time: 18min
Sample: Human serum, plasma (EDTA anticoagulant), whole blood (EDTA anticoagulant)
Reference range: <175ng/mL
Storage and Stability:
✭Detection Buffer is stable for 12 months at 2°C ~8°C.
✭Sealed Test Device is stable for 12 months at 4°C～30°C.
•Lipoprotein associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is composed of 441 amino acids and has a molecular weight of 45 kDa. It is produced by macrophages and is expressed in greater concentrations in atherosclerotic lesions.
•Lipids are fats in the blood. Lipoproteins are combinations of fats and proteins that carry the fats in the bloodstream. Lp-PLA2 in blood indicates the presence of fatty deposits in the arteries that are at risk of rupturing and causing heart disease or stroke.
•Lp-PLA2 is a novel and unique biomarker highly specific for vascular inflammation and atherosclerosis (AS). It is regulated by inflammatory mediators and has a strong pro-inflammatory and pro-atherosclerosis effect.
•It is released into the bloodstream in large quantities when the AS plaque has progressed to a severe level or is about to rupture. The test of Lp-PLA2 in blood can therefore reflect the degree of inflammation in AS.
Figure 1. Lp-PLA2 and the stability of atheromatous plaques
•《American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease (2017)》
Measure Lp-PLA2, which in some studies has demonstrated more specificity than hsCRP, when it is necessary to further stratify an individual’s atherosclerotic cardiovascular disease (ASCVD) risk, especially in the presence of hsCRP elevations.
•《Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association(2014)》
Measurement of inflammatory markers such as hs-CRP or Lp-PLA2 in patients without cardiovascular disease (CVD) may be considered to identify patients who may be at increased risk of stroke.
•《European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)》
Lp-PLA2 may be measured as part of a refined risk assessment in patients at high risk of a recurrent acute atherothrombotic event.
•《2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary》
Lp-PLA2 might be reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults.
•Assessment of the inflammation of atherosclerosis and its stability
•Prediction of coronary heart disease and ischemic stroke
•Warning the occurrence of myocardial infarction and cerebral thrombosis
•Assessment of recurrence risk of cardiovascular and cerebrovascular embolic diseases
•Assess the effectivity of treatment in atherosclerosis-related diseases
Figure 2. The role of Lp-PLA2 in cardiovascular disease
